Zenas BioPharma (NASDAQ:ZBIO) Trading 10.2% Higher - Time to Buy?

Key Points

• Zenas BioPharma shares increased by 10.2%, trading at $16.98 after a previous close of $15.41, with a trading volume decrease of 31% from the average.
• Analyst ratings show a positive outlook, with a price target of $35.00 from Wedbush and $30.00 from HC Wainwright, both under "outperform" and "buy" ratings.
• In its recent earnings report, Zenas BioPharma exceeded expectations with a revenue of $10 million and a smaller loss per share of ($0.80) against the estimated ($1.15).

Zenas BioPharma, Inc. (NASDAQ:ZBIO - Get Free Report) was up 10.2% during mid-day trading on Monday . The stock traded as high as $16.99 and last traded at $16.98. Approximately 125,846 shares were traded during mid-day trading, a decline of 31% from the average daily volume of 183,550 shares. The stock had previously closed at $15.41.

Analyst Ratings Changes

Several analysts have issued reports on ZBIO shares. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Zenas BioPharma in a research note on Friday, May 16th. Wedbush reaffirmed an "outperform" rating and set a $35.00 target price on shares of Zenas BioPharma in a report on Thursday, May 15th.

Zenas BioPharma Price Performance

The firm has a market capitalization of $634.98 million and a P/E ratio of -4.28. The stock's 50-day moving average price is $11.79.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last issued its quarterly earnings results on Thursday, May 15th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.15) by $0.35. The business had revenue of $10.00 million for the quarter, compared to analysts' expectations of $5.00 million.

Institutional Investors Weigh In On Zenas BioPharma

A number of hedge funds have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund purchased a new stake in Zenas BioPharma during the first quarter valued at $49,000. Nuveen LLC purchased a new stake in Zenas BioPharma during the first quarter valued at $250,000. Finally, Jefferies Financial Group Inc. purchased a new stake in Zenas BioPharma during the first quarter valued at $348,000.

Zenas BioPharma Company Profile

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.